Balanced news tone
News Sentiment
SCNI sentiment intelligence
Scinai Immunotherapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
50 relevant articles
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-0.4% over one week, -22.3% over four weeks, trend inactive, and below fair value.
Scinai Immunotherapeutics Company Profile & Introduction
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
79/100 classification
One-week reaction
-0.4%
Price digesting
Trend fit
Trend inactive
-22.3% over four weeks
Fair value
-93.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
10
Neutral
35
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
grafa.com
Direct company coverage
Scinai Immunotherapeutics reports Q1 2026 financial results
Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit of $3.6 million for Q1 2026, a significant turnaround from a loss in the prior year, primarily due to a $6.2 million non-cash bargain purchase gain from its Recipharm Israel acquisition. Despite this, total revenues de
- Tone
- Positive 64/100
- Event
- Deals and strategy
- Published
- 10 Jun 2026 12:10
- Source
- grafa.com
dars.gov.et
Direct company coverage
Scinai Immunotherapeutics (SCNI) Q4 2023 Earnings: EPS Surpasses Estimates Amid Continued Development Progress - EPS Surprise History
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 31 May 2026 07:00
- Source
- dars.gov.et
dars.gov.et
Direct company coverage
Scinai Immunotherapeutics (SCNI) Declines 7.25%, Eyes Key Support at $0.43 - Ichimoku Kumo Twist
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- dars.gov.et
PR Newswire
Direct company coverage
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 11:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 11:30
- Source
- PR Newswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Scinai raises $2.61M to expand drug manufacturing, fund programs
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- Stock Titan
PR Newswire
Direct company coverage
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- PR Newswire
Quiver Quantitative
Direct company coverage
Scinai Immunotherapeutics jumps on $2.61M private placement financing | SCNI Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- Quiver Quantitative
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
PR Newswire
Direct company coverage
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 01 Apr 2026 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 17 Feb 2026 08:00
- Source
- PR Newswire
Kalkine
Direct company coverage
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) Share Price, SCNI Stock News, SCNI Share Price & Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Nov 2025 23:35
- Source
- Kalkine
BioPharm International
Direct company coverage
Scinai Immunotherapeutics Forms CDMO Subsidiary in US
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2024 08:00
- Source
- BioPharm International
TradingView
Direct company coverage
SCNI Stock Price and Chart — NASDAQ:SCNI
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Sep 2023 21:39
- Source
- TradingView
MarketBeat
Direct company coverage
Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Sep 2023 16:35
- Source
- MarketBeat